Commonwealth Equity Services Inc acquired a new position in shares of Clovis Oncology, Inc. (NASDAQ:CLVS) during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 2,903 shares of the biopharmaceutical company’s stock, valued at approximately $239,000.
Other hedge funds and other institutional investors also recently modified their holdings of the company. Phocas Financial Corp. bought a new stake in Clovis Oncology during the second quarter worth approximately $112,000. Capital Analysts LLC bought a new stake in Clovis Oncology during the third quarter worth approximately $111,000. Advisors Asset Management Inc. increased its stake in Clovis Oncology by 160.7% during the second quarter. Advisors Asset Management Inc. now owns 1,895 shares of the biopharmaceutical company’s stock worth $177,000 after acquiring an additional 1,168 shares during the last quarter. Cypress Capital Management LLC WY increased its stake in Clovis Oncology by 272.7% during the third quarter. Cypress Capital Management LLC WY now owns 2,050 shares of the biopharmaceutical company’s stock worth $169,000 after acquiring an additional 1,500 shares during the last quarter. Finally, Bank of Montreal Can increased its stake in Clovis Oncology by 284.9% during the second quarter. Bank of Montreal Can now owns 2,702 shares of the biopharmaceutical company’s stock worth $253,000 after acquiring an additional 2,000 shares during the last quarter.
Shares of Clovis Oncology, Inc. (NASDAQ:CLVS) opened at $59.31 on Tuesday. The company has a debt-to-equity ratio of 0.94, a quick ratio of 3.16 and a current ratio of 3.19. Clovis Oncology, Inc. has a twelve month low of $35.38 and a twelve month high of $99.45.
Several brokerages have issued reports on CLVS. Leerink Swann restated an “outperform” rating and set a $90.00 target price (down previously from $107.00) on shares of Clovis Oncology in a research report on Wednesday, November 15th. Stifel Nicolaus restated a “buy” rating and set a $125.00 target price on shares of Clovis Oncology in a research report on Friday, November 3rd. Morgan Stanley dropped their target price on Clovis Oncology from $89.00 to $86.00 and set an “overweight” rating for the company in a research report on Thursday, November 2nd. Barclays began coverage on Clovis Oncology in a research report on Monday, October 23rd. They set an “overweight” rating and a $105.00 target price for the company. Finally, Zacks Investment Research upgraded Clovis Oncology from a “hold” rating to a “buy” rating and set a $95.00 target price for the company in a research report on Tuesday, October 17th. Eight investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. Clovis Oncology presently has an average rating of “Buy” and an average price target of $86.15.
In related news, insider Gillian C. Ivers-Read sold 3,000 shares of the business’s stock in a transaction that occurred on Monday, October 16th. The stock was sold at an average price of $84.54, for a total value of $253,620.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold 9,000 shares of company stock valued at $653,220 in the last quarter. 12.50% of the stock is owned by company insiders.
ILLEGAL ACTIVITY WARNING: This piece of content was first posted by Community Financial News and is the property of of Community Financial News. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of international copyright laws. The original version of this piece of content can be accessed at https://www.com-unik.info/2017/12/05/commonwealth-equity-services-inc-acquires-shares-of-2903-clovis-oncology-inc-clvs.html.
About Clovis Oncology
Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.
Want to see what other hedge funds are holding CLVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Clovis Oncology, Inc. (NASDAQ:CLVS).
What are top analysts saying about Clovis Oncology Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Clovis Oncology Inc. and related companies.